Abstract
Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Current Gene Therapy
Title: Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Volume: 3 Issue: 6
Author(s): Francis Dupont
Affiliation:
Keywords: Autonomous Parvovirus-Based Vectors, mammalian cells, DNA viruses, cancer gene therapy, oncotropism
Abstract: Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.
Export Options
About this article
Cite this article as:
Dupont Francis, Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors, Current Gene Therapy 2003; 3 (6) . https://dx.doi.org/10.2174/1566523034578104
DOI https://dx.doi.org/10.2174/1566523034578104 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Hemichannels in Cerebral Ischemia
Current Molecular Medicine MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Aquaporin and Blood Brain Barrier
Current Neuropharmacology Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Using the Concept of Chous Pseudo Amino Acid Composition to Predict Enzyme Family Classes: An Approach with Support Vector Machine Based on Discrete Wavelet Transform
Protein & Peptide Letters Cyclooxygenase-2 (COX-2) Mediates Arsenite Inhibition of UVB-Induced Cellular Apoptosis in Mouse Epidermal Cl41 Cells
Current Cancer Drug Targets Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Imaging Malignant Gliomas with 99mTc-MIBI Brain Single-Photon Emission Computed Tomography
Current Medical Imaging Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders
Current Neuropharmacology Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Incorporating Link Information in Feature Selection for Identifying Tumor Biomarkers by Using miRNA-mRNA Paired Expression Data
Current Proteomics Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry